craft-sa-dev Home  

PMC:1283364 / 746-1667 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T261 0-2 PRP denotes We
T263 3-7 VBP denotes have
T262 8-17 VBN denotes generated
T264 18-19 DT denotes a
T266 20-30 JJ denotes transgenic
T267 31-36 NN denotes mouse
T265 37-42 NN denotes model
T268 43-47 WDT denotes that
T270 48-59 RB denotes genetically
T269 60-66 VBZ denotes mimics
T271 67-70 DT denotes the
T272 71-77 NN denotes arrest
T273 78-80 IN denotes of
T274 81-83 NN denotes Aβ
T275 84-94 NN denotes production
T276 95-103 VBN denotes expected
T277 104-108 IN denotes from
T278 109-118 NN denotes treatment
T279 119-123 IN denotes with
T280 124-133 NN denotes secretase
T281 134-144 NNS denotes inhibitors
T282 144-145 . denotes .
T283 145-231 sentence denotes These mice overexpress mutant APP from a vector that can be regulated by doxycycline.
T284 146-151 DT denotes These
T285 152-156 NNS denotes mice
T286 157-168 VBP denotes overexpress
T287 169-175 NN denotes mutant
T288 176-179 NN denotes APP
T289 180-184 IN denotes from
T290 185-186 DT denotes a
T291 187-193 NN denotes vector
T292 194-198 WDT denotes that
T294 199-202 MD denotes can
T295 203-205 VB denotes be
T293 206-215 VBN denotes regulated
T296 216-218 IN denotes by
T297 219-230 NN denotes doxycycline
T298 230-231 . denotes .
T299 231-330 sentence denotes Under normal conditions, high-level expression of APP quickly induces fulminant amyloid pathology.
T300 232-237 IN denotes Under
T302 238-244 JJ denotes normal
T303 245-255 NNS denotes conditions
T304 255-257 , denotes ,
T305 257-261 JJ denotes high
T307 261-262 HYPH denotes -
T306 262-267 NN denotes level
T308 268-278 NN denotes expression
T309 279-281 IN denotes of
T310 282-285 NN denotes APP
T311 286-293 RB denotes quickly
T301 294-301 VBZ denotes induces
T312 302-311 JJ denotes fulminant
T314 312-319 NN denotes amyloid
T313 320-329 NN denotes pathology
T315 329-330 . denotes .
T316 330-490 sentence denotes We show that doxycycline administration inhibits transgenic APP expression by greater than 95% and reduces Aβ production to levels found in nontransgenic mice.
T317 331-333 PRP denotes We
T318 334-338 VBP denotes show
T319 339-343 IN denotes that
T321 344-355 NN denotes doxycycline
T322 356-370 NN denotes administration
T320 371-379 VBZ denotes inhibits
T323 380-390 JJ denotes transgenic
T325 391-394 NN denotes APP
T324 395-405 NN denotes expression
T326 406-408 IN denotes by
T327 409-416 JJR denotes greater
T329 417-421 IN denotes than
T328 422-424 CD denotes 95
T330 424-425 NN denotes %
T331 426-429 CC denotes and
T332 430-437 VBZ denotes reduces
T333 438-440 NN denotes Aβ
T334 441-451 NN denotes production
T335 452-454 IN denotes to
T336 455-461 NNS denotes levels
T337 462-467 VBN denotes found
T338 468-470 IN denotes in
T339 471-484 JJ denotes nontransgenic
T340 485-489 NNS denotes mice
T341 489-490 . denotes .
T342 490-596 sentence denotes Suppression of transgenic Aβ synthesis in this model abruptly halts the progression of amyloid pathology.
T343 491-502 NN denotes Suppression
T345 503-505 IN denotes of
T346 506-516 JJ denotes transgenic
T348 517-519 NN denotes Aβ
T347 520-529 NN denotes synthesis
T349 530-532 IN denotes in
T350 533-537 DT denotes this
T351 538-543 NN denotes model
T352 544-552 RB denotes abruptly
T344 553-558 VBZ denotes halts
T353 559-562 DT denotes the
T354 563-574 NN denotes progression
T355 575-577 IN denotes of
T356 578-585 NN denotes amyloid
T357 586-595 NN denotes pathology
T358 595-596 . denotes .
T359 596-749 sentence denotes However, formation and disaggregation of amyloid deposits appear to be in disequilibrium as the plaques require far longer to disperse than to assemble.
T360 597-604 RB denotes However
T362 604-606 , denotes ,
T363 606-615 NN denotes formation
T364 616-619 CC denotes and
T365 620-634 NN denotes disaggregation
T366 635-637 IN denotes of
T367 638-645 NN denotes amyloid
T368 646-654 NNS denotes deposits
T361 655-661 VBP denotes appear
T369 662-664 TO denotes to
T370 665-667 VB denotes be
T371 668-670 IN denotes in
T372 671-685 NN denotes disequilibrium
T373 686-688 IN denotes as
T375 689-692 DT denotes the
T376 693-700 NNS denotes plaques
T374 701-708 VBP denotes require
T377 709-712 RB denotes far
T378 713-719 RBR denotes longer
T379 720-722 TO denotes to
T380 723-731 VB denotes disperse
T381 732-736 IN denotes than
T383 737-739 TO denotes to
T382 740-748 VB denotes assemble
T384 748-749 . denotes .
T385 749-921 sentence denotes Mice in which APP synthesis was suppressed for as long as 6 mo after the formation of Aβ deposits retain a considerable amyloid load, with little sign of active clearance.
T386 750-754 NNS denotes Mice
T388 755-757 IN denotes in
T390 758-763 WDT denotes which
T391 764-767 NN denotes APP
T392 768-777 NN denotes synthesis
T393 778-781 VBD denotes was
T389 782-792 VBN denotes suppressed
T394 793-796 IN denotes for
T395 797-799 RB denotes as
T397 800-804 JJ denotes long
T398 805-807 IN denotes as
T396 808-809 CD denotes 6
T399 810-812 NN denotes mo
T400 813-818 IN denotes after
T401 819-822 DT denotes the
T402 823-832 NN denotes formation
T403 833-835 IN denotes of
T404 836-838 NN denotes Aβ
T405 839-847 NNS denotes deposits
T387 848-854 VBP denotes retain
T406 855-856 DT denotes a
T408 857-869 JJ denotes considerable
T409 870-877 NN denotes amyloid
T407 878-882 NN denotes load
T410 882-884 , denotes ,
T411 884-888 IN denotes with
T412 889-895 JJ denotes little
T413 896-900 NN denotes sign
T414 901-903 IN denotes of
T415 904-910 JJ denotes active
T416 911-920 NN denotes clearance
T417 920-921 . denotes .
R112 T261 T262 nsubj We,generated
R113 T263 T262 aux have,generated
R114 T264 T265 det a,model
R115 T265 T262 dobj model,generated
R116 T266 T265 amod transgenic,model
R117 T267 T265 compound mouse,model
R118 T268 T269 dep that,mimics
R119 T269 T265 relcl mimics,model
R120 T270 T269 advmod genetically,mimics
R121 T271 T272 det the,arrest
R122 T272 T269 dobj arrest,mimics
R123 T273 T272 prep of,arrest
R124 T274 T275 compound Aβ,production
R125 T275 T273 pobj production,of
R126 T276 T275 acl expected,production
R127 T277 T276 prep from,expected
R128 T278 T277 pobj treatment,from
R129 T279 T278 prep with,treatment
R130 T280 T281 compound secretase,inhibitors
R131 T281 T279 pobj inhibitors,with
R132 T282 T262 punct .,generated
R133 T284 T285 det These,mice
R134 T285 T286 nsubj mice,overexpress
R135 T287 T288 compound mutant,APP
R136 T288 T286 dobj APP,overexpress
R137 T289 T286 prep from,overexpress
R138 T290 T291 det a,vector
R139 T291 T289 pobj vector,from
R140 T292 T293 dep that,regulated
R141 T293 T291 relcl regulated,vector
R142 T294 T293 aux can,regulated
R143 T295 T293 auxpass be,regulated
R144 T296 T293 agent by,regulated
R145 T297 T296 pobj doxycycline,by
R146 T298 T286 punct .,overexpress
R147 T300 T301 prep Under,induces
R148 T302 T303 amod normal,conditions
R149 T303 T300 pobj conditions,Under
R150 T304 T301 punct ", ",induces
R151 T305 T306 amod high,level
R152 T306 T308 compound level,expression
R153 T307 T306 punct -,level
R154 T308 T301 nsubj expression,induces
R155 T309 T308 prep of,expression
R156 T310 T309 pobj APP,of
R157 T311 T301 advmod quickly,induces
R158 T312 T313 amod fulminant,pathology
R159 T313 T301 dobj pathology,induces
R160 T314 T313 compound amyloid,pathology
R161 T315 T301 punct .,induces
R162 T317 T318 nsubj We,show
R163 T319 T320 mark that,inhibits
R164 T320 T318 ccomp inhibits,show
R165 T321 T322 compound doxycycline,administration
R166 T322 T320 nsubj administration,inhibits
R167 T323 T324 amod transgenic,expression
R168 T324 T320 dobj expression,inhibits
R169 T325 T324 compound APP,expression
R170 T326 T320 prep by,inhibits
R171 T327 T328 amod greater,95
R172 T328 T330 nummod 95,%
R173 T329 T328 quantmod than,95
R174 T330 T326 pobj %,by
R175 T331 T320 cc and,inhibits
R176 T332 T320 conj reduces,inhibits
R177 T333 T334 compound Aβ,production
R178 T334 T332 dobj production,reduces
R179 T335 T332 prep to,reduces
R180 T336 T335 pobj levels,to
R181 T337 T336 acl found,levels
R182 T338 T337 prep in,found
R183 T339 T340 amod nontransgenic,mice
R184 T340 T338 pobj mice,in
R185 T341 T318 punct .,show
R186 T343 T344 nsubj Suppression,halts
R187 T345 T343 prep of,Suppression
R188 T346 T347 amod transgenic,synthesis
R189 T347 T345 pobj synthesis,of
R190 T348 T347 compound Aβ,synthesis
R191 T349 T343 prep in,Suppression
R192 T350 T351 det this,model
R193 T351 T349 pobj model,in
R194 T352 T344 advmod abruptly,halts
R195 T353 T354 det the,progression
R196 T354 T344 dobj progression,halts
R197 T355 T354 prep of,progression
R198 T356 T357 compound amyloid,pathology
R199 T357 T355 pobj pathology,of
R200 T358 T344 punct .,halts
R201 T360 T361 advmod However,appear
R202 T362 T361 punct ", ",appear
R203 T363 T361 nsubj formation,appear
R204 T364 T363 cc and,formation
R205 T365 T363 conj disaggregation,formation
R206 T366 T363 prep of,formation
R207 T367 T368 compound amyloid,deposits
R208 T368 T366 pobj deposits,of
R209 T369 T370 aux to,be
R210 T370 T361 xcomp be,appear
R211 T371 T370 prep in,be
R212 T372 T371 pobj disequilibrium,in
R213 T373 T374 mark as,require
R214 T374 T370 advcl require,be
R215 T375 T376 det the,plaques
R216 T376 T374 nsubj plaques,require
R217 T377 T378 advmod far,longer
R218 T378 T374 advmod longer,require
R219 T379 T380 aux to,disperse
R220 T380 T374 xcomp disperse,require
R221 T381 T382 mark than,assemble
R222 T382 T374 advcl assemble,require
R223 T383 T382 aux to,assemble
R224 T384 T361 punct .,appear
R225 T386 T387 nsubj Mice,retain
R226 T388 T389 prep in,suppressed
R227 T389 T386 relcl suppressed,Mice
R228 T390 T388 pobj which,in
R229 T391 T392 compound APP,synthesis
R230 T392 T389 nsubjpass synthesis,suppressed
R231 T393 T389 auxpass was,suppressed
R232 T394 T389 prep for,suppressed
R233 T395 T396 advmod as,6
R234 T396 T399 nummod 6,mo
R235 T397 T396 amod long,6
R236 T398 T396 quantmod as,6
R237 T399 T394 pobj mo,for
R238 T400 T389 prep after,suppressed
R239 T401 T402 det the,formation
R240 T402 T400 pobj formation,after
R241 T403 T402 prep of,formation
R242 T404 T405 compound Aβ,deposits
R243 T405 T403 pobj deposits,of
R244 T406 T407 det a,load
R245 T407 T387 dobj load,retain
R246 T408 T407 amod considerable,load
R247 T409 T407 compound amyloid,load
R248 T410 T387 punct ", ",retain
R249 T411 T387 prep with,retain
R250 T412 T413 amod little,sign
R251 T413 T411 pobj sign,with
R252 T414 T413 prep of,sign
R253 T415 T416 amod active,clearance
R254 T416 T414 pobj clearance,of
R255 T417 T387 punct .,retain